FIELD: medicine, pharmaceuticals.
SUBSTANCE: invention relates to compound of general formula I having structure of triazole[4,5-d]pyrimidine derivatives, or pharmaceutically acceptable salts, or prodrugs thereof. Disclosed is method for application of said compound or pharmaceutically acceptable salt thereof to produce pharmaceutical for treatment and prophylaxis of conditions ameliorated with blockage of adenosine A2A receptors. Also disclosed are pharmaceutical composition including compound of formula I, or pharmaceutically acceptable salt, or prodrug thereof in combination with pharmaceutically acceptable carrier or excipient. Said pharmaceutical compositions may be administered to subject by peroral, rectal, parantheral, transdermal, subdermal, etc. methods. Pharmaceutical of present invention are useful in treatment of Parkinson's disease, depression, cognitive or mental disturbances, acute or chronic pain, narcolepsy, etc.
EFFECT: composition of improved neuroprotective characteristics.
50 cl, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
DIAMINOTRIAZOLES, SUITABLE AS INHIBITORS OF PROTEIN KINASES | 2003 |
|
RU2350606C2 |
SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 2013 |
|
RU2607081C2 |
INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | 2017 |
|
RU2757457C2 |
5-SUBSTITUTED INDAZOLE AS KINASE INHIBITORS | 2008 |
|
RU2487873C2 |
MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | 2020 |
|
RU2822388C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
COMPOUNDS OF FORMULA (I) AND FORMULA (A), PHARMACEUTICAL COMPOSITION, MEDICINAL PRODUCT, USE AND METHOD OF OBTAINING COMPOUNDS OF FORMULA (I) | 2018 |
|
RU2822758C2 |
SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | 2014 |
|
RU2802185C2 |
Authors
Dates
2008-02-20—Published
2002-01-10—Filed